Alfresa Holdings Corporation FY2027 Q1 Earnings Report

Quick View

Executive Summary

This quarter resulted in a substantial decline in profit despite higher revenue, as increases in selling, general and administrative expenses, extraordinary losses, and the high tax burden compressed net income. Revenue was ¥7,889.6B (+4.1% YoY), Operating Income was ¥56.0B (-19.6%), and Ordinary Income was ¥60.9B (-20.5%). Consolidated Net Income was limited to ¥26.2B (-47.9%), including ¥24.76B attributable to owners of the parent (-50.5%). While growth in the core wholesale business for prescription pharmaceuticals and related products drove overall revenue, the increase in SG&A expenses (+5.1%) exceeded the growth in gross profit (+1.8%), resulting in a decline in operating profitability. In addition, extraordinary losses of ¥10.2B, including impairment losses on investment securities, and an effective tax rate of 48.6% further reduced net income.

Factors Affecting Results

【Revenue】Revenue was ¥7,889.6B (+4.1% YoY). The wholesale business for prescription pharmaceuticals and related products, which accounts for approximately 90% of the revenue mix, led overall performance at ¥7,098.0B (+4.6%). The self-medication wholesale business declined to ¥661.7B (-1.1%), while the manufacturing business declined to ¥119.6B (-5.3%). In contrast, the dispensing pharmacy and related business increased to ¥94.4B (+3.6%).

【Profit and Loss】Operating Income was ¥56.0B (-19.6%), and Ordinary Income was ¥60.9B (-20.5%). SG&A expenses of ¥471.7B (+5.1%) grew faster than gross profit of ¥527.6B (+1.8%), causing the operating margin to decline to 0.7% from 0.9% in the previous year. Extraordinary losses of ¥10.2B, including ¥7.5B in impairment losses on investment securities, were recorded as temporary factors, resulting in Profit Before Tax of ¥51.0B. The effective tax rate increased to 48.6% from the equivalent of approximately 42.0% in the previous year. Consequently, consolidated Net Income was ¥26.2B (-47.9%), while Net Income attributable to owners of the parent was ¥24.76B (-50.5%). The divergence between Ordinary Income and Net Income was primarily attributable to extraordinary losses and the high tax burden. The results were characterized by higher revenue but lower profit.

Segment Analysis

The wholesale business for prescription pharmaceuticals and related products recorded revenue of ¥7,098.0B (approximately 90% of the mix, +4.6% YoY) and Operating Income of ¥66.2B (-0.2%, operating margin 0.9%), resulting in higher revenue but nearly flat profit. The self-medication wholesale business recorded revenue of ¥661.7B (-1.1%) and Operating Income of ¥5.4B (-40.4%, operating margin 0.8%), with a notable decline in profitability. The pharmaceuticals and related products manufacturing business recorded revenue of ¥119.6B (-5.3%) and an Operating Loss of ¥6.2B, moving from a small profit in the previous year into the red, with an operating margin of -5.2%. The dispensing pharmacy and related business recorded revenue of ¥94.4B (+3.6%) and an Operating Loss of ¥5.0B (-13.2%, operating margin -5.3%), remaining unprofitable. The combined operating results of the three segments other than the core wholesale business were negative, making profitability improvement in non-core segments a key challenge for raising the Company-wide margin.

Key Financial Indicators

【Profitability】The Operating Margin declined to 0.7% from 0.9% in the previous year, the Ordinary Income Margin declined to 0.8% from 1.0%, and the consolidated Net Profit Margin declined to 0.3% from 0.7%. ROE remained at 0.5%. Under a low-margin, high-volume earnings structure with a gross margin of 6.7% versus 6.8% in the previous year, the increase in the SG&A ratio to 6.0% from 5.9% was the primary cause of the decline in profitability.【Cash Quality】Accounts receivable and notes receivable had a turnover period of approximately 81 days, while inventories stood at approximately 20 days. Accounts payable and notes payable stood at approximately 113 days, creating a negative cash conversion cycle in which trade payables exceeded the combined balance of accounts receivable and inventories, reflecting the trade-credit structure characteristic of the wholesale industry.【Investment Efficiency】Against total assets of ¥15,097.0B, quarterly revenue was ¥7,889.6B, representing a ratio of 0.52x. The Company’s ability to generate revenue relative to its asset base is limited when considered together with its low profitability.【Financial Soundness】The Equity Ratio was 32.2% versus 33.7% in the previous year, the current ratio was 120.9%, and the quick ratio was approximately 92.4%. Interest-bearing debt, comprising total borrowings of ¥100B and bonds of ¥200B, or ¥300B in total, was below cash and deposits of ¥1,782.7B, indicating that the Company maintains a substantially net-cash financial position.

Cash Flow Analysis

As the cash flow statement was not disclosed, cash trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥1,782.7B, down ¥148.0B from ¥1,930.7B in the same period of the previous year. Along with the increase in revenue, accounts receivable and notes receivable rose to ¥6,987.1B from ¥6,827.1B, while accounts payable and notes payable also increased to ¥9,141.7B from ¥8,820.3B, indicating an expansion in working capital in line with business growth. Meanwhile, treasury stock increased by ¥149.9B to ¥365.4B from ¥215.5B, suggesting that share repurchases contributed to the decline in cash balances. The structure in which accounts payable exceed the combined balance of accounts receivable and inventories has continued, with no change observed in the working capital structure dependent on supplier credit.

Quality of Earnings

The recurring earnings base remains broadly stable under a low-margin, high-volume wholesale structure; however, attention should be paid to the significant impact of extraordinary losses on net income this quarter. Extraordinary losses were ¥10.2B, primarily comprising ¥7.5B in impairment losses on investment securities and ¥1.0B in losses on disposal of fixed assets, both of which can be classified as temporary factors. Non-operating income was limited to ¥7.5B, including ¥3.9B in dividend income and ¥0.6B in interest income, representing less than 0.1% of revenue. Its scale was limited, and the primary drivers of earnings volatility were extraordinary items and the tax burden rather than non-operating items. Against an Ordinary Income Margin of 0.8%, the consolidated Net Profit Margin declined to 0.3%, primarily due to the higher tax burden compared with the previous year, reflected in an effective tax rate of 48.6% and corporate income taxes of ¥24.8B against Profit Before Tax of ¥51.0B. In terms of working capital, the Company has maintained a negative cash conversion cycle in which accounts payable exceed the combined balance of accounts receivable and inventories. Excluding temporary extraordinary gains and losses, the quality of earnings is not considered to have been materially impaired.

Earnings Forecast and Guidance

Progress against the full-year Company forecast was 25.1% for revenue (¥7,889.6B/¥31,440.0B), compared with 16.5% for Operating Income (¥56.0B/¥339.0B), 16.6% for Ordinary Income (¥60.9B/¥366.0B), and 11.9% for Net Income attributable to owners of the parent (¥24.76B/¥208.0B). Profit progress was therefore significantly below the simple proportional benchmark of 25%. While revenue is tracking in line with the plan, profit progress as of Q1 is lagging due to increased SG&A expenses, extraordinary losses, and the high tax burden. Given that the full-year plan itself assumes declines of Operating Income YoY-6.3% and Ordinary Income YoY-5.3%, recovery in the second half is a prerequisite for achieving the plan. The Company has not revised either its earnings forecast or dividend forecast as of this quarter, and the plans remain unchanged.

Shareholder Returns

The full-year dividend forecast is ¥71 per share. Based on 175,413 thousand shares, calculated by deducting 15,887 thousand treasury shares from 191,300 thousand issued shares, the annual dividend payout is estimated at approximately ¥124.5B. This implies a Payout Ratio of approximately 59.9% against the full-year Net Income forecast attributable to owners of the parent of ¥208.0B. Treasury stock also increased by ¥149.9B to ¥365.4B from ¥215.5B, indicating progress in share repurchases. Given that the Net Income progress rate was only 11.9% as of Q1, the sustainability of the dividend plan should be monitored together with the subsequent recovery in earnings, taking into account the level of cash and deposits at ¥1,782.7B.

Risk Factors

1. Margin Compression Risk: The SG&A ratio increased to 6.0% from 5.9%, while the gross margin was 6.7% versus 6.8% in the previous year, causing the Operating Margin to decline to 0.7% from 0.9%. In a low-margin, high-volume business structure, cost increases have a significant impact on profit. If the current situation continues, in which the SG&A growth rate of +5.1% exceeds the gross profit growth rate of +1.8%, profitability may come under further pressure.

2. Profitability of Non-Core Segments: The pharmaceuticals and related products manufacturing business recorded an Operating Loss of ¥6.2B, moving from a small profit in the previous year into the red, while the dispensing pharmacy and related business recorded an Operating Loss of ¥5.0B, with the loss widening by 13.2% YoY. Although the core wholesale business for prescription pharmaceuticals and related products accounts for approximately 90% of the revenue mix, the combined operating results of the three non-core segments were negative. The concentration of the business portfolio and profitability improvements in loss-making segments remain challenges.

3. Volatility in Extraordinary Items and Tax Burden: The Company recorded extraordinary losses of ¥10.2B this quarter, including ¥7.5B in impairment losses on investment securities, while the effective tax rate also reached a high level of 48.6%, reflecting corporate income taxes of ¥24.8B against Profit Before Tax of ¥51.0B. These factors significantly reduced Net Income relative to Ordinary Income and may continue to contribute to earnings volatility depending on market conditions and tax-related factors.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

Both the Operating Margin and Net Profit Margin were significantly below the industry median, positioning the Company’s low-margin structure at a relatively low level among its peers.

Growth and Capital Efficiency

The revenue growth rate was slightly above the industry median, indicating relatively solid top-line growth within the industry.

Source: Compiled by the Company

Key Takeaways from the Results

1. Revenue increased by +4.1%, exceeding the industry median of +3.1%; however, the Operating Margin of 0.7% and Net Profit Margin of 0.3% were both significantly below the industry medians of 4.3% and 3.8%, respectively. The gap between revenue growth and profitability was a defining feature of these results.

2. The SG&A growth rate of +5.1% exceeded the gross profit growth rate of +1.8%, directly causing the decline in Operating Income (-19.6%). The divergence between the pace of cost increases and earnings growth is a key structural factor that will determine future margin trends.

3. Full-year progress was 25.1% for revenue, compared with 16.5% for Operating Income and 11.9% for Net Income. The extent to which the effects of the temporary and tax-related factors—extraordinary losses of ¥10.2B and an effective tax rate of 48.6%—are resolved in the second half will be a key focus going forward.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly available data using a residual income model (Ohlson-type model with an explicit 5-year fade period). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥2,340–¥2,473 at Cost of Equity ±1%, and ¥2,393–¥2,412 at ω±0.1.

Notes:

• As forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the quarter-end are used; there is a timing difference relative to the full-year forecast.
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-07 / This value does not predict or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting professionals as necessary.

---End of Report---